Takeda invested $20m in the round and is providing $80m in development financing through a strategic partnership deal.

Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.

Boston Scientific, which paid $25m for a 25% stake in the venous stent developer two years ago, has agreed to buy the company in full.

Glaucoma therapy spinout Quethera will become a unit of drug manufacturer Astellas Pharma, providing exits to investors Cambridge Enterprise, UCEF III and UK2IS.

Heather Preston, formerly managing director at TPG Biotech, has taken a managing partner position at Nan Fung-backed Pivotal BioVenture Partners.

Novo led a $60m series B round for achondroplasia drug developer Therachon that also featured Pfizer Ventures.

The oversubscribed round included Pfizer, Novartis, Merck Group and AbbVie, and boosted the cancer drug developer's overall funding to $120m.

Illumina, GV and Orient Life supported a $72m series C round for MIT spinout SQZ Biotechnology, with the money set to fund therapies for solid tumours and autoimmunity.

Illumina, GV and Orient Life supported a $72m series C round for SQZ Biotechnology, with the money set to fund therapies for solid tumours and autoimmunity.